NEW YORK – BGI said late on Friday that its Real-Time Fluorescent RT-PCR kit for detecting SARS-CoV-2 (also known as 2019-nCoV) has received CE-IVD marking and is now commercially available in markets recognizing the designation.
BGI's kit is a qualitative in vitro nucleic acid amplification assay that detects 2019-mCoV, the cause of COVID-19, using reverse transcriptase PCR from throat swab and bronchoalveolar lavage fluid samples.